Bristol Myers reports two-year POETYK PsA-2 results for Sotyktu
Bristol Myers Squibb announced positive through-two-years data from the Phase 3 POETYK PsA-2 study, including its open-label extension, for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.